Healthcare
Palisade Bio, Inc.(PALI)
Live Price
Offline$1.71
-3.93% today
1Y Change
+143.84%
Window
Jun 25, 2025 โ Jun 16, 2026
- Market Cap
- $330.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +97.1%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 25, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Palisade Bio, Inc. (PALI) is a Healthcare stock with a market cap of $330.00M and listed on NASDAQ. The stock last traded around $1.71 and up 143.8% across the available one-year price window (Jun 25, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +97.1%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +97.1%, free cash flow +11.0% with operating margin 0.0% and ROIC -13.9%. Stock Foundry combines PALI price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 11, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +97.1%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +1.1% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 11, 2026 | โ | -1.0% | -6.7% | -12.9% |
2026 Mar 23, 2026 | -100.0% | +4.7% | -6.8% | +46.6% |
2025 Nov 10, 2025 | -18.8% | +2.8% | +16.9% | +7.3% |
Benchmark Edge
PALI vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
PALI
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
PALI Max Drawdown
-56.45%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PALI and SPY.
Company Overview
Palisade Bio, Inc.
NASDAQ Capital Market
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.
- Leadership
- J. D. Finley
- IPO Date
- Mar 30, 2007
- Employees
- 8
- Street Address
- 5800 Armada Drive
- Mailing
- Carlsbad, CA, 92008
- Region
- Carlsbad, CA, US
- Reporting Currency
- USD
- Investor Line
- 858 704 4900
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 0.9
Growth
- Revenue
- 0.0%
- EPS
- +97.1%
- Free Cash Flow
- +11.0%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -47.8%
- ROIC
- -13.9%
Balance Sheet
- Debt/Equity
- 0.00
- Current Ratio
- 28.95
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.